← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Anagin
Indianapolis, IN
$10,520,534
Total funding
6
Grants
Funding over time
peak $3.1M · FY2014–24$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,520,534 · 6
By mechanism
R44$5,881,072 · 2
U44$3,311,688 · 1
R43$1,327,774 · 3
Investigators at Anagin
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel treatment of posttraumatic stress disorder$1,619,914
R44 · FY2018 · MH
Development of novel small molecule analgesics modulating the nNOS-NOS1AP protein-protein interaction$1,498,044
R44 · FY2018 · NS
Novel treatment of posttraumatic stress disorder$1,373,142
R44 · FY2017 · MH
Development of novel small molecule analgesics modulating the nNOS-NOS1AP protein-protein interaction$1,103,900
R44 · FY2019 · NS
Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics$1,034,659
U44 · FY2023 · NS
Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics$962,495
U44 · FY2022 · NS
Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics$814,748
U44 · FY2024 · NS
Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics$499,786
U44 · FY2021 · NS
High throughput screen to identify small molecule analgesics targeting nNOS-NOS1AP protein-protein interactions$367,687
R43 · FY2016 · NS
Novel treatment of posttraumatic stress disorder$348,749
R43 · FY2014 · MH
Novel treatment of posttraumatic stress disorder$343,957
R43 · FY2015 · MH
Development of novel small molecule analgesics modulating the nNOS-NOS1AP protein-protein interaction$286,072
R44 · FY2020 · NS
nNOS-PSD95 inhibitors as novel treatments for TBI$267,381
R43 · FY2016 · NS